Identical prices of medicines across the European Union – it is assumed jumped by some Members of the European Parliament project, which is to be the realization of the postulate that access to medicines was equal and solidarity in all Member States. Averaging the prices of medicines in the EU mean, however, high prices in pharmacies in Polish woman, and the specter of crisis, domestic pharmaceutical industry.
Poland is now one of the cheapest countries in the European Union in terms of drug prices. With last year’s report by Deloitte shows that the average producer price net is the second lowest price across the EU.MEPs argue that standardization of prices will bring their decline, but even if in fact there would be a reduction in the average prices of medicines in the European Union, in the case of Polish market, there can be no other scenario than even a several fold increase in the price.
as on Monday revealed health Minister Konstanty Radziwill, a common setting of drug prices in Europe are lobbying even some ministers of health of countries of Western Europe.
– at the last joint meeting of health ministers in the European Council objected very strongly and I have good support health ministers of countries in our region of the European Union that such a solution is totally unacceptable to us – said Radziwill. – I think that we act effectively to prevent such a possibility – rated.
Minister Radziwill said that the effect of the low prices of medicines in Poland is the so-called reverse distribution chain, that is, removal of medicines abroad. This entails problems with the availability of certain drugs in pharmacies. As assured, the department is working on an amendment to the provisions concerning pricing mechanisms of drugs.
– It’s very complicated processes that may lead to the fact that effective drug prices in Poland will keep at a low level, but the official price will be high enough that this phenomenon is the export of drugs limit – said Radziwill.
equal drug prices, why not equal pay?
the idea of unification of the price of medicines in the European Union European critically evaluate, experts pharmaceutical market.
– I think that proposed by MEPs alignment of prices of medicines throughout the European Union would be very difficult to carry out because of the complexity of this market – says Wirtualna Dr. Stanislaw Maksymovych expert center for the Club of the Jagiellonian. – I expect that this is one of those ideas that sweep the European Parliament, but ultimately none of them shows – he says.
However, notes the expert, the European Union has already controlling some markets, for example. telecommunications, and therefore can not be ruled out that the alignment of prices is a real prospect. – It certainly would not be beneficial for us, would result in higher prices. Drug prices in Poland are among the lowest in the European Union, while the degree of the refund is the lowest – he said.
– Trading in pharmaceutical products governed by the laws of the market, as well as a deep intervention in the market generally more it disturb than bring to order it – says Dr. Maksymovych. – Alignment of prices could lead to consequences that even now it is difficult to predict, eg. Might be problems with the availability of certain drugs – warns.
– If you are to be equal to the price of drugs, I would like to also have equal salaries , pensions and national income – tells us, in turn, Irena Rej, president of the Chamber of Commerce “Polish Pharmacy”. – Either we have a free market economy or controlled. You can not equate everything to the same level, because we are not equal. We have many other problems with the pharmaceutical industry, which are more important than the harmonization of prices in the EU – said.
According to Rej, the introduction of equal price means the destruction of the Polish pharmaceutical industry. – Any adjustment of Polish producers to EU standards entail huge financial costs, and these regulations will mean additional costs. If the purpose of these changes is to destroy the local pharmaceutical industries, the goal will be achieved – he says.
– I think these are just fantasies and fitting, and the idea is completely utopian. Each country has its own system of reimbursement, any other system of health care, other treatment schedules – says a representative of the Polish pharmaceutical industry.
– If the prices in Europe would be averaged could mean their growth with us – says Wirtualna Polska Elżbieta Piotrowska -Rutkowska, president of the Supreme Pharmaceutical Council. – It is difficult to assess how the mechanism of compensation for Polish would then have to apply the EU.
He noted that the project is only at the concept stage and the final settlement is still very far away. – Certainly a huge plus of such a solution would be inhibited exports of Polish massive amounts of drugs and life-saving health, since no difference range in a natural way would render it unprofitable – states.
Piotrowska-Rutkowska that it had already introduced four years ago in Poland mechanism fixed prices. – The result was a drop in prices of many commonly used drugs. Today, this list has nearly 4 tys.pozycji and is still growing. You have complete control over billions of zlotys dopłacanymi to the reimbursed drugs – he said.
These effects, let him be and reward
It is difficult to assess whether the idea Members the Europarliament can count on the implementation, but at the same time own idea of capsizing drug market in the Old Continent has the same pharmaceutical industry.
As in June, told Reuters, European Federation of industry and Organisation of pharmaceutical Associations (EFPIA) aims the total change in pricing in the European Union. From disclosed by Reuters internal report EFPIA that pharmaceutical companies want to be paid on the basis of clinical effects, not the number of sold tablets.
– If the product is not able to meet their clinical promise, society does not You should pay for it. On the other hand, if another product brings more benefits than expected, this added value should be rewarded – explained François Bouvy of EFPIA.
No comments:
Post a Comment